1 Selective serotonin reuptake inhibitors (SSRI) – sales, withdrawal ...

1988 Medicines Control Agency, Committee on
Safety of Medicines (1988).
Benzodiazepines, dependence and
withdrawal symptoms.
Current problems in Pharmacovigilance, 21,
1-2.
1993 Circular about prescription of addictive
drugs. Circular number 110 28/06/1993.
Danish National Board of Health.
in only a small proportion of
benzodiazepine takers the
number of patients involved
may be substantial. The risks
of dependence could be
reduced by more trained
prescribing of
benzodiazepine.
There has been concern for
many years regarding
benzodiazpine dependence
(Br.Med.J,1980:280:910-12).
Such dependence is
becoming increasingly
worrying.
[Usage in Denmark is above
the international average. It
is not the intension with
these guidelines to question
current treatment. They are
for short term treatment. For
severe, disabling cases.]
Article in the
bulletin sent out
from the MCA
to doctors,
pharmacists,
dentists and
coroners.
Circular – a law
text
SSRIs
Year Reference Citation Genre
1993 Medicines Control Agency,
Committee on Safety of Medicines
(1993). Dystonia and withdrawal
symptoms with paroxetine (Seroxat).
Current problems in pharmacovigilance 19, February.
1996 Price J.S, Waller P.C., Wood S.M,
Mackay A.V.P. A comparison of
the post-marketing safety of four
selective serotonin re-uptake inhibitors
including the investigation of symptoms
occurring on withdrawal. British Journal
Clinical Pharmacology. 1996;42:757-63.
We have received
78 reports of
symptoms occurring
on withdrawal of
paroxetine,
including dizziness,
sweating, nausea,
insomnia, tremor
and confusion. Such
reactions have been
reported more often
with paroxetine than
with other SSRIs.
It appears that the
reports represent
genuine withdrawal
reactions, but the
low frequency of
reporting per
thousand
prescriptions,
together with the
published
Article in the
bulletin sent out
from the MCA
to doctors,
pharmacists,
dentists and
coroners
Scientific paper